hotspot -WSS

hotspot

author：entertainment 2025-10-02 17:22:50 - browse：81493

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： As pharma fights Medicare drug negotiation, hospitals, docs silent

WSS

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Guardant Health colon cancer test endorsed by FDA advisory panel

The Bio Revolution is changing business and society

How to make AI work for medicine

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Stroke rates rising, especially in working

Wikipedia

hotspot

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

How Long Island became the ‘eugenics capital of the world’

As demand for Covid shots wanes, Moderna seeks its next success

What AAP's gender

BioMarin wins approval for gene therapy to treat hemophilia A

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Bright Health sells Medicare Advantage business to Molina

Departing Stanford president retracts two papers

Sports medicine is finally prioritizing gender equality

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

entertainment

Drug firms test therapies to halt Alzheimer’s before symptoms arise

What AAP's gender

Apellis safety probe of eye disease drug centers on injection needle

Hospitals need to get ahead of regulations on climate change

What AAP's gender

Stroke rates rising, especially in working

focus

hotspot

knowledge

hotspot